Video

Anna Vioral on Multidisciplinary Chemotherapy Safety Standards

Anna Vioral, RN, OCN, from West Penn Allegheny Health System, on Multidisciplinary Chemotherapy Safety Standards.

Anna Vioral, MSN, MEd, RN, OCN®, Oncology, West Penn Allegheny Health System, summarizes a three year effort to standardize and integrate a set of multidisciplinary chemotherapy safety standards, which used the preexisting recommendations from the American Society of Clinical Oncology (ASCO) and Oncology Nursing Society (ONS).

Vioral notes that a number of chemotherapy and targeted agents have now expanded to non-oncology spaces, which includes rheumatoid arthritis, lupus, nephritis, multiple sclerosis, and ectopic pregnancies. Regardless of the setting, these agents still contain harmful and severe side effects. The goal of the project was to develop interdisciplinary standards, which are required to manage the complex processes involved in chemotherapy delivery.

The study developed 16 system wide guidelines based on the 31 combined preexisting ONS and ASCO safety standards. The 16 guidelines promote a multidisciplinary approach to prescribing, ordering, mixing, dispensing, administering, and safe handling of chemotherapy.

Vioral notes it is important to include each entity in the standards because each group plays an important role in ensuring safe chemotherapy delivery.

<<<

View more from the 2012 ONS Congress

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.